Table 3.
Ongoing phase III trials with targeted agents in advanced gastric cancer
| Targeted pathway | Agent/selection biomarker | Trial design | ClinicalTrials.gov identifier |
|---|---|---|---|
| HER | Varlitinib/HER1 and HER2 | Phase II/III 1st-line comparing varlitinib plus mFOLFOX6 versus placebo plus mFOLFOX6 | NCT03130790 |
| Nimotuzumab/HER1 | ENRICH 2nd-line comparing irinotecan with or without nimotuzumab in Asian patients | NCT01813253 | |
| Angiogenesis | Ramucirumab/HER2(−) | ARMANI comparing maintenance therapy with ramucirumab plus paclitaxel versus continuation of 1st-line chemotherapy | NCT02934464 |
| Regorafenib/none | INTEGRATEII 3rd-line comparing regorafenib versus placebo | NCT02773524 | |
| Apatinib/none | ANGEL 3rd-line comparing apatinib versus placebo | NCT03042611 | |
| Fruquintinib/none | FRUTIGA 2nd-line comparing fruquintinib plus paclitaxel versus placebo plus paclitaxel | NCT03223376 | |
| Anlotinib/none | ALTER0503 3rd-line comparing anlotinib versus placebo | NCT02461407 | |
| PD-1/PD-L1 | Nivolumab with or without ipilimumab/HER2(−) | CheckMate649 1st-line comparing nivolumab plus ipilimumab or nivolumab plus chemotherapy against chemotherapy alone | NCT02872116 |
| Nivolumab/HER2(−) | ATTRACTION-4 1st-line comparing nivolumab plus chemotherapy versus placebo plus chemotherapy | NCT02746796 | |
| Pembrolizumab/PD-L1 | KEYNOTE-063 2nd-line comparing pembrolizumab versus paclitaxel in Asian patients | NCT03019588 | |
| Pembrolizumab/HER2 | KEYNOTE-811 1st-line comparing pembrolizumab plus trastuzumab in combination with chemotherapy versus placebo plus trastuzumab in combination with chemotherapy | NCT03615326 | |
| Pembrolizumab/none | KEYNOTE-590 1st-line in esophageal including gastroesophageal junction cancer comparing chemotherapy versus chemotherapy plus pembrolizumab in Chinese patients | NCT03189719 | |
| Avelumab/HER2(−) | JAVELIN Gastric 100 comparing maintenance therapy with avelumab versus continuation of 1st-line chemotherapy | NCT02625610 | |
| FGFR2 | FPA144/FGFR2 & HER2(−) | FIGHT/1st-line comparing FPA144 plus mFOLFOX6 versus placebo plus mFOLFOX6 | NCT03694522 |
| Claudin 18.2 | IMAB362/claudin 18.2 & HER2(−) | SPOTLIGHT/1st-line comparing IMAB362 plus mFOLFOX6 versus placebo plus mFOLFOX6 | NCT03504397 |
HER human epidermal growth factor receptor, mFOLFOX6 5-fluorouracil/leucovorin/oxaliplatin, PD-1 programmed death-1, PD-L1 programmed death ligand 1, FGFR2 fibroblast growth factor receptor 2